era martedì
oggi compio 24 anni di forum
e mi son fatto un regalo
Vedi l'allegato 2990697
aggiungo questo articolo, che descrive meglio cosa sta succedendo e cosa significa per le terapie dei tumori colorettali.
Cardiff Oncology Reveals Promising Onvansertib Results in Metastatic Colorectal Cancer Trial
Cardiff Oncology, Inc. has
unveiled new clinical data from its ONSEMBLE trial, demonstrating the efficacy of onvansertib in combination with FOLFIRI/bev for treating RAS-mutated metastatic colorectal cancer (mCRC) patients. Despite the discontinuation of the Phase 2 trial to pivot towards a first-line treatment approach, the results mark a significant milestone in cancer therapy.
Promising Data from the ONSEMBLE Trial
The ONSEMBLE trial's discontinuation in August 2023, under the guidance of the FDA, was a strategic move to refocus on first-line RAS-mutated mCRC treatments. The trial had enrolled 23 patients across three arms before its closure, continuing treatment as per protocol. The data echoed the efficacy of onvansertib in providing substantial benefits to bev naïve patients, a cohort that showed no objective responses in the control arm. This differentiation underscores onvansertib's potential in enhancing standard care efficacy, particularly in a first-line setting.
Shifting Focus to First-Line Treatment
Cardiff Oncology's strategic decision to prioritize first-line treatment for RAS-mutated mCRC aligns with the FDA's recommendations and the absence of new therapy approvals for this cancer type in two decades. Fairooz Kabbinavar, MD, FACP, and Chief Medical Officer at Cardiff Oncology, emphasized the significance of these findings in bolstering the case for onvansertib's use early in treatment protocols. The anticipation for the topline results of the first-line CRDF-004 trial, expected in mid-2024, is high amongst the medical community and patients alike.
Conference Call and Future Prospects
Cardiff Oncology will host a conference call and live webcast to discuss these findings further, providing an opportunity for investors and interested parties to gain deeper insights into the trial results and the company's strategic direction. This dialogue will be essential in understanding the broader implications of onvansertib's trial outcomes and the potential reshaping of treatment paradigms for mCRC patients.
The development of onvansertib represents a beacon of hope for mCRC patients, particularly those with RAS mutations. As Cardiff Oncology continues to refine its clinical development program, the oncology community watches keenly, hopeful for a new era in cancer treatment that could significantly improve patient outcomes and quality of life.
For more detailed information on the biology of cancer treatment and the potential of PLK1 inhibition, readers can explore Biology | An Open Access Journal from MDPI.
